How Maxwell® Contributes to Higher Reproducibility for DNA and RNA Extraction in Gene Therapy
About This Webcast
Time: 9am CDT / 10am EDT / 3pm London / 4pm Amsterdam-Paris Gene therapy has emerged as one of the most promising therapeutic fields in recent years, particularly for neurodegenerative disorders. The GENOV Innovation Unit at the Paris Brain Institute is dedicated to advancing gene and cell therapy strategies for conditions such as ALS, Parkinson’s disease, and Alzheimer’s disease, as well as rare lysosomal storage disorders including mucopolysaccharidosis and metachromatic leukodystrophy. With a strong translational focus, the team develops therapies from early proof-of-concept (POC) studies through large animal models and into clinical applications. Their work involves comparing and optimizing multiple AAV vectors and evaluating different routes of administration. To generate robust data for regulatory submissions, they require highly reproducible analysis processes, particularly for biodistribution and RNA expression readouts. Join us for this webinar, where featured speakers from the GENOV Innovation Unit will share how they established a streamlined analysis pipeline by integrating the Maxwell® automated DNA/RNA extraction system to enhance reproducibility. Accurate biodistribution assessment is critical in gene therapy development. It confirms that therapeutic vectors reach the intended target tissues or cells, informs dosing to achieve the right balance of efficacy and safety, and provides essential evidence that links gene presence to biological effects. Moreover, precise biodistribution data are required for regulatory approval, help mitigate long-term risks such as insertional mutagenesis, and ultimately support the safe and effective translation of gene therapies to patients. In this webinar, you will learn about: Advances in gene and cell therapy for neurodegenerative and rare disorders How Maxwell® automated nucleic acid extraction system supports reproducible biodistribution and RNA expression analysis Insights into how accurate biodistribution ensures evaluation of treatment safety, efficacy, and regulatory compliance
Speakers
Dr. Françoise PIGUET
Head of GENOV Innovation Unit , Paris Brain Institute
Dr. Françoise PIGUET is heading the GENOV innovation unit in Paris Brain Institute focused on development of gene and cell therapy approaches for neurodegenerative diseases. Since 2006, she contributed to the field of neurodegenerative diseases and development of AAV based- gene therapy approaches first on leukodystrophies, Huntington, Friedreich Ataxia, ALS, Parkinson and mucopolysaccharidosis. She previously developed a clinical trial on metachromatic leukodystrophy and generated 8 patents for notably a gene therapy approach for Friedreich Ataxia as well as for Rett syndrome, MLD, ALS and MPS as well as cell therapies. More recently, Françoise is working on development of new routes of delivery to efficiently target the central and peripheral nervous system. She is an expert of preclinical studies to fill IND and CTA applications.
Dr Sylvie Jacquot
Head of Molecular Biology, GENOV Innovation Unit , Paris Brain Institute
Dr Sylvie JACQUOT is head of molecular biology innovation at GENOV at the Paris Brain Institute. Previously at the Mouse Clinic Institute (Illkirch), she led the high-throughput genotyping platform for 10 years and co-led the genetic engineering department for four years. Her career demonstrates solid expertise in Molecular Biology, creation of genetically modified models (mutagenesis, transgenesis), and a commitment to the development and optimization of Genetic engineering techniques. Since 2022, she specialized in AAV detection and RNA readout in gene therapy approaches.
Dr. Ruchika Sharma
Product Specialist - Genomic Solutions , Promega Corporation
Ruchika Sharma is a Product Specialist in the Genomic Solutions Group at Promega Corporation. She manages a portfolio of Promega’s sample preparation products for in-vitro diagnostics and manual purification and works with customers in different market segments globally to understand and address their unmet sample preparation needs. She also works with Promega’s cross-functional teams to provide solutions tailored to customer needs for any specific applications of Promega’s products, including the Wizard® HMW DNA Extraction Kit for isolation of high-molecular weight DNA for long read sequencing. Ruchika holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science and did her postdoctoral training at the National Institutes of Health and the University of Wisconsin-Madison, focusing on the role of molecular chaperones in protein folding and human diseases.